© 2021 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
A single dose of the HIV capsid inhibitor reduced viral load in highly treatment-experienced people.
A study looked at the fat composition of people who switched their antiretrovirals to include an integrase inhibitor.
ViiV’s two-drug Dovato also boasted a high genetic barrier to the development of viral resistance.
MK-8507, a long-acting NNRTI, will be tested in a weekly regimen with islatravir.
A study found no difference in outcomes based on whether participants took oral meds for a month before switching to injectables.
A mid-stage trial of the experimental drug islatravir plus Pifeltro did not see notable shifts in measures of kidney function.
This is according to a three-year study in which people switched from a stable HIV regimen to Delstrigo.
None of the people who experienced virologic failure on regimens containing the experimental drug had a viral load of 200 or higher.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
